scholarly journals Expression and clinical significance of programmed death‑1 on lymphocytes and programmed death ligand‑1 on monocytes in the peripheral blood of patients with cervical cancer

2017 ◽  
Author(s):  
Ying Zhang ◽  
Weipei Zhu ◽  
Xueguang Zhang ◽  
Qiuxia Qu ◽  
Liyuan Zhang
Keyword(s):  
Cervical Cancer ◽  
Clinical Significance ◽  
Peripheral Blood ◽  
Programmed Death Ligand 1 ◽  
Programmed Death ◽  
Programmed Death 1

scholarly journals Elevated Expression of Programmed Death-1 and Programmed Death Ligand-1 Negatively Regulates Immune Response against Cervical Cancer Cells

2016 ◽  
Vol 2016 ◽  
pp. 1-11 ◽  
Author(s):  
Zhifang Chen ◽  
Nannan Pang ◽  
Rong Du ◽  
Yuejie Zhu ◽  
Lingling Fan ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Immune Response ◽  
Cancer Cells ◽  
Cancer Patients ◽  
Peripheral Blood ◽  
High Expression ◽  
Programmed Death Ligand 1 ◽  
Programmed Death ◽  
Cervical Cancer Cells ◽  
Programmed Death 1

The present study is to measure the expression of programmed death-1 (PD-1) and programmed death ligand-1 (PD-L1), as well as its clinical significance in cervical cancer patients. Our results showed that different T cell subsets in patients with cervical cancer had high expression of PD-1, and DCs had high expression of PD-L1. High expression of PD-1 on Treg cells in cervical cancer patients facilitated the production of TGF-βand IL-10 but inhibited the production of IFN-γ. Cervical cancer elevated the expression of PD-1 and PD-L1 in mRNA level. PD-1 expression in peripheral blood of cervical cancer patients was related with tumor differentiation, lymph node metastasis, and invasiveness. PD-1/PD-L1 pathway inhibited lymphocyte proliferation but enhanced the secretion of IL-10 and TGF-βin vitro. In summary, our findings demonstrate that elevated levels of PD-1/PD-L1, TGF-β, and IL-10 in peripheral blood of cervical cancer patients may negatively regulate immune response against cervical cancer cells and contribute to the progression of cervical cancer. Therefore, PD-1/PD-L1 pathway may become an immunotherapy target in the future.

scholarly journals Clinical significance of programmed death 1/programmed death ligand 1 pathway in gastric neuroendocrine carcinomas

2019 ◽  
Vol 25 (14) ◽  
pp. 1684-1696 ◽  
Author(s):  
Min-Wei Yang ◽  
Xue-Liang Fu ◽  
Yong-Sheng Jiang ◽  
Xiao-Jing Chen ◽  
Ling-Ye Tao ◽  
...  
Keyword(s):  
Clinical Significance ◽  
Programmed Death Ligand 1 ◽  
Programmed Death ◽  
Programmed Death 1 ◽  
Neuroendocrine Carcinomas
Sign in / Sign up

Export Citation Format

Share Document